Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes

Read the full 329 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE